寵物癌症藥物市場－全球產業規模、佔有率、趨勢、機會及預測（依治療方法、動物種類、癌症種類、地區及競爭格局分類，2021-2031年）

全球寵物癌症藥物市場預計將從 2025 年的 4.6769 億美元大幅成長至 2031 年的 8.1641 億美元，複合年成長率為 9.73%。

此細分市場涵蓋專門針對伴侶動物惡性腫瘤開發的藥物和生物製藥，包括免疫療法、化療和分子標靶藥物。市場成長的主要促進因素是寵物預期壽命的延長（導致癌症發病率老齡化成長而增加）以及人與動物之間日益緊密的聯繫，如今飼主對獸醫腫瘤科的醫療服務水平提出了與人類同等的要求。此外，診斷準確性的提高使得腫瘤能夠更早被發現，從而即時需要超越基本安寧療護的有效治療方法。

市場擴張的一大障礙是先進腫瘤治療的高昂費用，這往往限制了沒有保險的寵物飼主獲得治療的機會。儘管存在這些經濟障礙，獸醫保健的總投入仍在持續成長，凸顯了飼主對寵物健康的高度重視。根據美國寵物用品協會 (APPA) 預測，到 2024 年，美國獸醫保健和產品銷售額預計將達到 398 億美元。如此巨大的支出表明，儘管先進治療方法的高昂費用帶來了挑戰，但仍有強大的經濟基礎來支持新型癌症治療方法的研發和商業化。

市場促進因素

全球寵物癌症治療市場正因新型標靶治療和免疫療法的研發而發生變革，標誌著治療方式正從傳統的特異性化療轉向精準治療。獸醫腫瘤學正日益採用精準醫療方法，利用單株抗體和自體疫苗來改善臨床療效並最大限度地減少副作用。這種以療效為導向的創新趨勢得益於免疫療法的最新成功，為希望延長寵物壽命的飼主提供了強力的證據。例如，2025年2月，Torigen Pharmaceuticals公司報告稱，其針對轉移性血管肉瘤犬的標靶免疫療法，與單純手術相比，可使犬隻的整體存活期延長3.5倍。這些成果正在加速這些先進藥物的商業性化應用。

同時，寵物健康保險覆蓋範圍的擴大也帶來了重要的經濟成長，降低了以往阻礙寵物獲得昂貴腫瘤治療的經濟門檻。隨著保險覆蓋率的提高，飼主更容易負擔昂貴的治療方案，從而將潛在需求轉化為實際的市場收入。 2025年4月，北美寵物健康保險協會（NAPHIA）報告稱，到2024年底，北美投保寵物總數將達到703萬隻，同比成長12.2%。這一不斷擴大的經濟安全網正鼓勵製藥公司增加對研發管線的投資。例如，2025年5月，禮來動物保健公司（Elanco Animal Health）將2025會計年度的創新收入目標從6.6億美元上調至7.4億美元，凸顯了將新一代獸藥推向市場的巨大商業性潛力。

市場挑戰

先進的腫瘤治療方法費用高昂，是限制全球寵物癌症治療市場成長的主要障礙。新興的標靶治療和化療雖然能改善臨床療效，但其高昂的價格往往令許多寵物主人望而卻步。由於缺乏廣泛的第三方報銷，經濟負擔幾乎完全落在飼主飼主身上，迫使許多人放棄根治性治療，轉而選擇費用較低的安寧療護。這種經濟壓力限制了藥物研發者的潛在市場規模，並降低了新藥研發的投資報酬率。

這項限制也源自於寵物保險普及率低，導致大多數飼主面臨意外高醫療費用的風險。根據北美寵物健康保險協會（NAPHIA）預測，到2024年，美國投保寵物總數將達到640萬隻，市場滲透率僅3.9%。由於大多數伴侶動物沒有保險，高附加價值療法的商業性可行性僅限於特定人群，這阻礙了市場擴張，儘管腫瘤疾病的發生率不斷上升。

市場趨勢

人工智慧 (AI) 在治療方案選擇中的應用正在革新獸醫腫瘤學，將臨床判斷從經驗通訊協定轉向數據驅動的精準醫療。 AI 演算法分析活體癌細胞反應和流式細胞技術數據，在化療給藥前預測化療，從而顯著減少試驗流程。這種功能性精準醫療方法使獸醫能夠根據每位患者獨特的生物學特徵最佳化治療方案，提高緩解率並最大限度地減少不必要的毒性。 ImpriMed 於 2024 年 9 月宣布，其 AI 驅動平台已成功指導超過 7500 例犬貓血液癌症患者的治療，證明了演算法決策支持在常規臨床實踐中的商業性擴充性。

同時，比較腫瘤學和「同一健康」模式正在加速新型治療方法的研發，這些療法充分利用了犬類自然發生的癌症與人類惡性腫瘤之間的生物學相似性。由於犬類腫瘤比囓齒動物異種移植模型更能有效預測人類藥物反應，製藥開發商正擴大將伴侶犬的臨床試驗納入開發平臺，使伴侶動物能夠更早獲得前沿的人類治療方法。這種雙贏局面產生了高度精確的臨床基因組資料集，推動了兩個物種的創新。例如，2024年10月，FidoCure宣布其分析了508例伴侶犬患者的基因組數據，並確定了可直接指導犬類和人類血管肉瘤治療策略的標靶治療效果。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球寵物癌症藥物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依治療方法（手術、放射線治療、化療、免疫療法、其他）
  • 動物種類（狗、貓、其他）
  • 癌症類型（淋巴瘤、肥大細胞瘤、乳癌/鱗狀細胞癌、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美寵物癌症藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲寵物癌症藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區寵物癌症藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲寵物癌症藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲寵物癌症藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球寵物癌症藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• CH Boehringer Sohn Ko. KG
• ELIAS Animal Health, LLC
• Zoetis Inc.
• AB Science SA
• Karyopharm Therapeutics, Inc.
• Vivesto AB
• Merial Inc.
• Elanco Animal Health, Inc.
• Dechra Pharmaceuticals PLC
• Torigen Pharmaceuticals Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Pet Cancer Therapeutics Market is projected to expand significantly, growing from USD 467.69 Million in 2025 to USD 816.41 Million by 2031, reflecting a 9.73% CAGR. This sector encompasses a specialized range of pharmaceutical and biologic agents, such as immunotherapies, chemotherapies, and targeted molecular drugs, all engineered to address malignancies in companion animals. The market's growth is primarily fueled by the increasing life expectancy of pets, which naturally leads to a higher prevalence of age-related cancers, and the strengthening human-animal bond that drives owners to seek veterinary oncology care comparable to human medical standards. Additionally, advancements in diagnostic precision allow for earlier tumor detection, creating an immediate demand for effective interventions beyond basic palliative care.

A major hurdle to broader market expansion is the high cost associated with advanced oncological regimens, which often restricts access for pet owners without insurance. Despite these financial barriers, overall investment in animal health continues to rise, highlighting the priority owners place on veterinary well-being. According to the American Pet Products Association, veterinary care and product sales in the United States reached $39.8 billion in 2024. This substantial expenditure demonstrates the strong economic foundation supporting the development and commercialization of new cancer therapies, even amidst the challenges posed by the high price points of these sophisticated treatments.

Market Driver

The landscape of the Global Pet Cancer Therapeutics Market is being transformed by the development of novel targeted therapies and immunotherapies, marking a significant shift away from traditional, non-specific chemotherapy. Veterinary oncology is increasingly adopting precision medicine approaches, utilizing monoclonal antibodies and autologous vaccines to enhance clinical outcomes while minimizing adverse effects. This transition towards efficacy-driven innovation is underscored by recent successes in immunotherapy, which provide compelling evidence to owners seeking life-extending options for their pets. for example, Torigen Pharmaceuticals reported in February 2025 that dogs with metastatic hemangiosarcoma treated with their targeted immunotherapy achieved a 3.5-fold increase in overall survival compared to surgery alone, a result that is accelerating the commercial adoption of these advanced agents.

Simultaneously, the expansion of pet health insurance coverage is acting as a crucial financial enabler, alleviating the economic barriers that historically limited access to premium oncological treatments. As insurance penetration deepens, pet owners are better equipped to afford expensive therapeutic regimens, converting latent demand into realized market revenue. The North American Pet Health Insurance Association reported in April 2025 that the total number of insured pets in North America reached 7.03 million at the end of 2024, representing a 12.2% annual increase. This growing financial safety net encourages pharmaceutical companies to invest heavily in their pipelines; for instance, Elanco Animal Health raised its 2025 innovation revenue target to between $660 million and $740 million in May 2025, highlighting the robust commercial potential of bringing next-generation veterinary therapeutics to market.

Market Challenge

The prohibitive cost of advanced oncological regimens presents a substantial barrier to the growth of the Global Pet Cancer Therapeutics Market. Although emerging targeted drugs and chemotherapies offer improved clinical outcomes, their high price points often render them inaccessible to a large segment of the pet-owning population. In the absence of widespread third-party reimbursement, the financial burden falls almost entirely on the pet owner, forcing many clients to forego curative treatment in favor of less expensive palliative options. This economic pressure constrains the addressable market for pharmaceutical developers and limits the return on investment for new drug development.

This constraint is intensified by the limited adoption of pet insurance, which leaves most owners vulnerable to sudden, high-cost medical expenses. According to the North American Pet Health Insurance Association, the total number of insured pets in the United States was 6.4 million in 2024, representing a market penetration rate of just 3.9%. Because the vast majority of companion animals lack coverage, the commercial viability of premium therapeutics is restricted to a narrow demographic, hampering broader market expansion despite the rising incidence of neoplastic diseases.

Market Trends

The application of Artificial Intelligence in treatment selection is revolutionizing veterinary oncology by shifting clinical decision-making from empirical protocols to data-driven precision. AI algorithms now analyze live tumor cell responses and flow cytometry data to predict the efficacy of specific chemotherapeutic agents before administration, significantly reducing trial-and-error in prescribing. This functional precision medicine approach allows veterinarians to tailor regimens to the unique biological profile of each patient, optimizing remission rates and minimizing unnecessary toxicity. According to ImpriMed in September 2024, the company's AI-driven platform had successfully guided treatment for over 7,500 canine and feline blood cancer patients, validating the commercial scalability of algorithmic decision support in routine practice.

Simultaneously, the leveraging of Comparative Oncology and One Health models is accelerating the development of novel therapeutics by utilizing the biological similarities between spontaneous canine cancers and human malignancies. Pharmaceutical developers are increasingly integrating pet dog clinical trials into their R&D pipelines, as canine tumors provide a more predictive model for human drug response than rodent xenografts, granting pets early access to cutting-edge human-grade therapies. This bi-directional benefit is generating high-fidelity clinico-genomic datasets that drive innovation across both species. For instance, FidoCure announced in October 2024 that it analyzed genomic data from 508 pet dog patients to identify targeted therapeutic outcomes that directly inform treatment strategies for both canine hemangiosarcoma and human angiosarcoma.

Key Market Players

• C.H. Boehringer Sohn Ko. KG
• ELIAS Animal Health, LLC
• Zoetis Inc.
• AB Science S.A.
• Karyopharm Therapeutics, Inc.
• Vivesto AB
• Merial Inc.
• Elanco Animal Health, Inc.
• Dechra Pharmaceuticals PLC
• Torigen Pharmaceuticals Inc

Report Scope

In this report, the Global Pet Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pet Cancer Therapeutics Market, By Therapy

• Surgery
• Radiotherapy
• Chemotherapy
• Immunotherapy
• Others

Pet Cancer Therapeutics Market, By Animal Type

• Canine
• Feline
• Others

Pet Cancer Therapeutics Market, By Cancer Type

• Lymphoma
• Mast Cell Cancer
• Mammary & Squamous Cell Cancer
• Others

Pet Cancer Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pet Cancer Therapeutics Market.

Available Customizations:

Global Pet Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pet Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others)
  • 5.2.2. By Animal Type (Canine, Feline, Others)
  • 5.2.3. By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pet Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Animal Type
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pet Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. Canada Pet Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Mexico Pet Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Cancer Type

7. Europe Pet Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Animal Type
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pet Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. France Pet Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. United Kingdom Pet Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Pet Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. Spain Pet Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Cancer Type

8. Asia Pacific Pet Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Animal Type
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pet Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. India Pet Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Japan Pet Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Cancer Type
  • 8.3.4. South Korea Pet Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Cancer Type
  • 8.3.5. Australia Pet Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Cancer Type

9. Middle East & Africa Pet Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Animal Type
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pet Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. UAE Pet Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. South Africa Pet Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Cancer Type

10. South America Pet Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Animal Type
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pet Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Colombia Pet Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. Argentina Pet Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pet Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. C.H. Boehringer Sohn Ko. KG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ELIAS Animal Health, LLC
• 15.3. Zoetis Inc.
• 15.4. AB Science S.A.
• 15.5. Karyopharm Therapeutics, Inc.
• 15.6. Vivesto AB
• 15.7. Merial Inc.
• 15.8. Elanco Animal Health, Inc.
• 15.9. Dechra Pharmaceuticals PLC
• 15.10. Torigen Pharmaceuticals Inc

16. Strategic Recommendations

17. About Us & Disclaimer